Teva Confirms Denosumab Is Part Of Its Biosimilar Pipeline

Prolia Biosimilar Asset Is In Phase III Development

 
• By Dean Rudge
  
Clinical_Trial_Tablet
Teva estimates study completion in December 2023 • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products